David Waugh,Daniel Longley,Pamela Maxwell,Melissa LaBonte Wilson
申请号：
US16643756
公开号：
US20200276164A1
申请日:
2018.08.31
申请国别(地区):
US
年份:
2020
代理人:
摘要：
This disclosure relates to an enhanced molecular-targeted approach that targets treatment-induced or native hypoxia present within cancers, specifically, but not limited to the treatment of metastatic prostate cancer with androgen deprivation therapy, such as anti-androgens. The disclosure describes the utility of combined inhibition of IL-8 and VEGF signalling to effect a combined therapeutic response of malignant disease, which is magnified under conditions of hypoxia. Thus, provided is a pharmaceutical combination for use in the treatment of cancer, the pharmaceutical combination comprising: a vascular endothelial growth factor (VEGF) signalling inhibitor； and an interleukin-8 (IL-8) signalling inhibitor； wherein said use comprises administration of the pharmaceutical combination to a patient receiving an anti-cancer therapy.
